Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090160 | 0.78 | MEN1 (0.43) | PIK3CDCASP3GSTO1LIPG | |
| SCHEMBL7673928 | 0.78 | VCAM1 (0.38) | PIK3CDCA2VCAM1 | |
| SCHEMBL29443939 | 0.76 | PIK3CD (0.37) | PIK3CDCASP3GSTO1LIPG | |
| SCHEMBL16090628 | 0.76 | PIK3CD (0.37) | PIK3CDCASP3GSTO1CA2LIPG | |
| SCHEMBL7258188 | 0.76 | PIK3CD (0.37) | PIK3CDCASP3GSTO1CA2LIPG | |
| SCHEMBL11466793 | 0.75 | — | — | |
| SCHEMBL12018085 | 0.74 | CASP3 (0.36) | PIK3CDCASP3GSTO1LIPG | |
| Hydrochloric Acid SCHEMBL3049835 | 0.74 | CASP3 (0.36) | PIK3CDCASP3GSTO1CA2LIPG | |
| SCHEMBL3927362 | 0.74 | CASP3 (0.36) | PIK3CDCASP3GSTO1CA2 | |
| SCHEMBL7046706 | 0.73 | VCAM1 (0.36) | PIK3CDCA2VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133610-A1 | INHIBITORY COMPOUNDS | LOQUS23 THERAPEUTICS LIMITED (GB) | 2025-06-26 | — | — | WO | disclosed |
| EP-4574817-A1 | INHIBITORY COMPOUNDS | LoQus23 Therapeutics Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-11241415-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor | NEKTAR THERAPEUTICS (US) | 2022-02-08 | — | — | US | disclosed |
| US-20190269652-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS | 2019-09-05 | — | — | US | disclosed |
| EP-3237388-B1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | NEKTAR THERAPEUTICS (US) | 2019-06-18 | — | — | US | disclosed |
| US-10197557-B2 | Small molecules for endothelial cell activation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170368029-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS | 2017-12-28 | — | — | US | disclosed |
| EP-3237388-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | Nektar Therapeutics (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016106133-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-07-03 | — | — | US | disclosed |
| CN-1425010-A | Cyclic compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-06-18 | — | — | CN | disclosed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| EP-1259499-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| US-6458783-B1 | INHIBITION OF FARNESYL TRANSFERASE, WHICH IS AN ENZYME INVOLVED IN RAS ONCOGENE EXPRESSION, IS EFFECTED BY COMPOUNDS OF THE FORMULAS OF BENODIAZEPINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001081322-A1 | NON-IMIDAZOLE BENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001060808-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368029-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | OPRK1, OPRM1, OPRD1 | PIK3CD 3568/4885CASP3 4371/4885GSTO1 2219/4885 |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | PIK3CD 2909/4885CASP3 3023/4885GSTO1 3741/4885 |
| US-20190269652-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | OPRK1, OPRM1, OPRD1 | PIK3CD 3568/4885CASP3 4371/4885GSTO1 2219/4885 |
| US-11241415-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor | OPRM1, OPRK1, OPRD1 | PIK3CD 3833/4885CASP3 4411/4885GSTO1 2165/4885 |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | MMP9, MMP1, MMP3 | PIK3CD 4758/4885CASP3 718/4885GSTO1 616/4885 |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | PIK3CD 2909/4885CASP3 3023/4885GSTO1 3741/4885 |
| US-10197557-B2 | Small molecules for endothelial cell activation | LIPG, VCAM1, SELE | PIK3CD 371/4885CASP3 978/4885GSTO1 1883/4885 |
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | OPRK1, OPRM1, OPRD1 | PIK3CD 3568/4885CASP3 4371/4885GSTO1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.